Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI and peer support close the opioid treatment gap?

NCT ID NCT06569667

Disease control Sponsor: Friends Research Institute, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether an AI-driven texting tool, combined with support from peer recovery coaches, can help Black and Latinx people who use opioids start buprenorphine treatment in primary care. Participants are enrolled from emergency departments and receive text messages with social services information, stigma reduction, and patient navigation. The study measures how many people link to opioid use disorder services and stay in treatment over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-driven texting tool combined with peer recovery coach support
What this could lead to
If effective, this approach could reduce racial disparities in opioid treatment access and help more Black and Latinx individuals start and stay on buprenorphine.
What could go wrong
The trial is small and early, so results may not apply broadly. The intervention depends on participants engaging with texts and coaches, which may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

94 people

The number who actually took part.

Started

Mar 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years of age; 2. fluent in English and/or Spanish; 3. self-reported non-prescription opioid use \<30 days prior to consent; 4. provision of informed consent; 5. planned stay in NYC ≥12 month; 6. self-identified Black and/or Latinx race/ethnicity; 7. positive urine toxicology for opioids per EMR records; 8. diagnosis of OUD per the Diagnostic and Statistical Manual of Mental Disorders-5 9. self-reported interest in initiating buprenorphine in primary care 10. must have a mobile phone data plan. Exclusion Criteria: 1. inability to comprehend text content written at a 3rd grade reading level; 2. physical or visual disability preventing mobile phone use; 3. self-reported receipt of medications for OUD in past 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid-use disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid-use disorder

Contacts and locations

Locations

  • NYC Health + Hospitals

    The Bronx, New York, 10451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.